TUDCA-ALS has started recruiting in the UK

TUDCA-ALS is a European Consortium (funded by the European Commission under the Horizon 2020 grant) involving top researchers from seven countries across Europe (see Figure 1). The Consortium aims to find a new treatment to slow down the progression of MND/ALS by conducting a clinical trial to investigate the safety and efficacy (effectiveness) of Tauroursodeoxycholic acid (also known as TUDCA).Read More »

Drug repurposing – harnessing the positive side effects of ‘old school’ drugs

Is it possible that a drug that treats congestive heart failure could improve respiration in people with MND? Or that a drug used to treat cancer could reduce motor neuron inflammation and possibly slow progression of the disease? In this blog we take a look at drug repurposing – using a drug developed to treat a particular disease to treat another that is unrelated – what it is, and what it might mean for people living with MND.Read More »